Cristina López‐Vicario, David Sebastián, Mireia Casulleras, Marta Duran‐Güell, Roger Flores‐Costa, Ferran Aguilar, Juan José Lozano, Ingrid W. Zhang, Esther Titos, Jing X. Kang, Antonio Zorzano, Makoto Arita, Joan Clària – 4 July 2022
Alexander J. Kovalic, Tai‐Ping Lee, Ben L. Da – 4 July 2022
Huapeng Lin, Terry Cheuk‐Fung Yip, Xinrong Zhang, Guanlin Li, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Jimmy Che‐To Lai, Stephen Lam Chan, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong – 4 July 2022
Amy Chang, Alexandra T. Strauss, Jennifer L. Alejo, Teresa P.‐Y. Chiang, Nicole F. Hernandez, Laura B. Zeiser, Brian J. Boyarsky, Robin K. Avery, Aaron A. R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik‐Wang, Allan B. Massie, William A. Werbel, Dorry L. Segev – 4 July 2022
Jihyun An, Seungbong Han, Ha Il Kim, Ju Hyun Shim – 3 July 2022 – To date, no studies have compared the new first‐line atezolizumab+bevacizumab with transarterial therapies combined with the prior standard‐of‐care, sorafenib, in patients with advanced hepatocellular carcinoma (HCC). We compared and ranked all relevant transarterial and targeted treatments competing with atezolizumab+bevacizumab for such disease, based on direct and indirect evidence.
Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jérôme Boursier, Philippe Mathurin, Céline Ribet, Victor Ledinghen, Marie Zins, Marie‐Aline Charles – 2 July 2022
Nitisha Mondia, Satender Pal Singh, Ajay Kumar Mishra – 2 July 2022
Adriana Perez, Nadia Ovchinsky – 1 July 2022
AASLD’s mission is to advance and disseminate the science and practice of hepatology and to promote liver health and quality patient care. See how we have advanced our mission by viewing our recent annual reports.